

# Andrew M Waters

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5295394/publications.pdf>

Version: 2024-02-01

13  
papers

1,488  
citations

933447

10  
h-index

1058476

14  
g-index

14  
all docs

14  
docs citations

14  
times ranked

3407  
citing authors

#	ARTICLE	IF	CITATIONS
1	Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and Growth. <i>Cancer Research</i> , 2022, 82, 90-104.	0.9	19
2	Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 762-774.	4.1	9
3	Validation of Isoform- and Mutation-Specific RAS Antibodies. <i>Methods in Molecular Biology</i> , 2021, 2262, 91-103.	0.9	2
4	Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. <i>Cell Reports</i> , 2021, 35, 109291.	6.4	15
5	CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. <i>Cell Reports</i> , 2021, 37, 110060.	6.4	14
6	Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. <i>Cancer Discovery</i> , 2020, 10, 104-123.	9.4	131
7	Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. <i>Cell Reports</i> , 2020, 31, 107764.	6.4	69
8	Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. <i>Nature Medicine</i> , 2019, 25, 628-640.	30.7	476
9	Differential Effector Engagement by Oncogenic KRAS. <i>Cell Reports</i> , 2018, 22, 1889-1902.	6.4	101
10	KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a031435.	6.2	563
11	Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies. <i>Science Signaling</i> , 2017, 10, .	3.6	51
12	Single Synonymous Mutations in KRAS Cause Transformed Phenotypes in NIH3T3 Cells. <i>PLoS ONE</i> , 2016, 11, e0163272.	2.5	10
13	Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surface. <i>Oncotarget</i> , 2016, 7, 86948-86971.	1.8	23